Company: SWKH
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001628280-25-025955
Chunk: 39

Company: SWK Holdings Corp
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 39
---
,830 $— $— $14,830     There were no liabilities measured at fair value on a nonrecurring basis as of March 31, 2025 and December 31, 2024.The following information is provided to help readers gain an understanding of the relationship between amounts reported in the accompanying unaudited condensed consolidated financial statements and the related market or fair value. The disclosures include financial instruments and derivative financial instruments measured at fair value on a recurring and non-recurring basis.The following table presents the fair value of financial assets as of March 31, 2025 (in thousands):Carrying ValueFair ValueLevel 1Level 2Level 3Financial AssetsFinance receivables, net$223,076 $223,076 $— $— $223,076 Finance receivables and related interest receivable held for sale (1)33,990 33,990 — — 33,990 Marketable investments455 455 442 — 13 Warrant assets4,245 4,245 — — 4,245 Foreign currency forward contract2,066 2,066 — — 2,066 (1) Non-recurring valuation as of March 19, 2025

20

The following table presents the fair value of financial assets and liabilities as of year ended December 31, 2024 (in thousands):Carrying ValueFair ValueLevel 1Level 2Level 3Financial AssetsFinance receivables, net$277,760 $277,760 $— $— $277,760 Marketable investments580 580 559 — 21 Warrant assets4,366 4,366 — — 4,366 Foreign currency forward contract2,475 2,475 — — 2,475 

Note 9. Revenue Recognition

The Company's Pharmaceutical Development segment recognizes revenues received from contracts with its customers by revenue source, as we believe it best depicts the nature, amount, timing and uncertainty of our revenue and cash flow. The Company's Finance Receivables segment does not have any revenues received from contracts with customers.The following table provides the contract revenue recognized by revenue source (in thousands):Three Months EndedMarch 31,20252024Pharmaceutical Development SegmentPharmaceutical Development 963 279 Total contract revenue$963 $279 The Company's contract liabilities represent advance